Study on Renoprotective effect of High Intensity Statin in Comparison with Moderate Intensity Statin in Patients with Ischemic Heart Disease and Chronic Kidney Disease
Article Sidebar
Main Article Content
Abstract
Objective: To study renoprotective effect based on eGFR and LDL-C reduction after treatment with high intensity statin (HIS) therapy compared to moderate intensity statin (MIS). Methods: This study was an analytical study with retrospective and prospective data collection in patients with coronary artery disease with eGFR in the range of 30-89 ml/min/1.73m2 and having no treatment with statins before. Outcome of the study was a decrease in eGFR and LDL-C levels from 1-3 years of follow-up in the HIS group compared to that in MIS group. Results: There were 158 participants--92 in HIS group and 66 in MIS group. In the MIS group, eGFR and LDL-C levels decreased by 2.42 ml/min/1.73m2 and 33.52 mg/dl, respectively. The HIS group had eGFR and LDL-C levels decreased by 1.93 ml/min/1.73m2 and 45.74 mg/dl, respectively. After controlling confounding factors, changes in eGFR and LDL-C in both groups were not different (eGFR; P = 0.702, 95% CI: -5.20-3.21, LDL-C; P = 0.136, 95% CI -2.33-17.05). Conclusion: HIS and MIS were not different in renoprotective effect in patients with ischemic heart disease with eGFR in the range of 30-89 ml/min/1.733m2. However, HIS group showed more reduction LDL-C levels, but not reaching statistically significant levels.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
World Health Organization. Prevention of recurrences of myocardial infarction and stroke study [online]. 2017 [cited 2017 Sep 1]. Available from: www.who. int/cardiovascular_diseases/priorities/secondary_preven tion/country/en/index1.html.
Bureau of Policy and Strategy, Ministry of Public Health. Causes of deaths: public health statistics [online]. 2015 [cited Sep 27, 2018]. Available form: bps.moph.go.th/new_bps/sites/default/files/health_statistic2558.pdf
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-65.
Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010; 25: 1567-75.
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guide lines. Circulation. 2004; 110: 588-636.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR /AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cho lesterol: A report of the American College of Cardio logy/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1182-e1186.
Kidney Disease Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease . Kidney Inter 2013; 3: 259–305.
Sanguankeo A, Upala S, Cheungpasitporn W, Ung prasert P, Knight EL. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PloS one 2015 ; 10: e0132970.
de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabe tes Endocrinol 2015; 3: 181-90.
Ma H, Liu Y, Xie H, Zhang G, Zhan H, Liu Z, et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine 2017; 96: e7351.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118
Baradaran A, Hasanpour Z, Kopaei MR. An update on renoprotective and nephrotoxicity of statins. Ann Res Antioxid 2016; 1: 16
Ching-Wei Tsai, I-Wen Ting, Hung-Chieh Yeh, Chin-Chi Kuo. Longitudinal change in estimated GFR among CKD patients: A 10-year follow-up study of an integrated kidney disease care program in Taiwan. PLoS One. 2017; 12: e0173843.
Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565-70.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889-934
Watson WC, Buchanan KD. Serum cholesterol levels after myocardial infraction. BMJ 1963; 21: 709 -12.
Rott D, Klempfner R, Goldenberg I, Leibowitz D. cholesterol levels decrease soon after acute myocar- dial infarction. Isr Med Assoc J. 2015; 17: 370-3.
Chin CW, Gao F, Le T, Tan R. Lipid goal attainment and prescription behavior in Asian patients with acute coronary syndromes: experience from a tertiary hospital. Clin Med Insights Cardiol. 2013;7: 51-7.
